624 related articles for article (PubMed ID: 17049234)
41. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
42. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
[TBL] [Abstract][Full Text] [Related]
43. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
Hu X; Stebbins CE
Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
[TBL] [Abstract][Full Text] [Related]
44. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease.
Zhou A; Hu J; Wang L; Zhong G; Pan J; Wu Z; Hui A
J Mol Model; 2015 Oct; 21(10):277. PubMed ID: 26438408
[TBL] [Abstract][Full Text] [Related]
45. Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE).
Araújo JQ; de Brito MA; Hoelz LV; de Alencastro RB; Castro HC; Rodrigues CR; Albuquerque MG
Eur J Med Chem; 2011 Jan; 46(1):39-51. PubMed ID: 21074294
[TBL] [Abstract][Full Text] [Related]
46. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
47. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
48. 3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method.
Temiz-Arpaci O; Tekiner-Gulbas B; Yildiz I; Aki-Sener E; Yalcin I
Bioorg Med Chem; 2005 Dec; 13(23):6354-9. PubMed ID: 15993083
[TBL] [Abstract][Full Text] [Related]
49. Combined 3D-QSAR modeling and molecular docking study on quinoline derivatives as inhibitors of P-selectin.
Zeng H; Cao R; Zhang H
Chem Biol Drug Des; 2009 Dec; 74(6):596-610. PubMed ID: 19843078
[TBL] [Abstract][Full Text] [Related]
50. 4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields.
Vitorović-Todorović MD; Juranić IO; Mandić LM; Drakulić BJ
Bioorg Med Chem; 2010 Feb; 18(3):1181-93. PubMed ID: 20061157
[TBL] [Abstract][Full Text] [Related]
51. A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition.
Guo J; Hurley MM; Wright JB; Lushington GH
J Med Chem; 2004 Oct; 47(22):5492-500. PubMed ID: 15481986
[TBL] [Abstract][Full Text] [Related]
52. Molecular Modeling Studies of Anti-Alzheimer Agents by QSAR, Molecular Docking and Molecular Dynamics Simulations Techniques.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Med Chem; 2020; 16(7):903-927. PubMed ID: 31385775
[TBL] [Abstract][Full Text] [Related]
53. GA strategy for variable selection in QSAR studies: application of GA-based region selection to a 3D-QSAR study of acetylcholinesterase inhibitors.
Hasegawa K; Kimura T; Funatsu K
J Chem Inf Comput Sci; 1999; 39(1):112-20. PubMed ID: 10094610
[TBL] [Abstract][Full Text] [Related]
54. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
Xiao J; Guo Z; Guo Y; Chu F; Sun P
Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
[TBL] [Abstract][Full Text] [Related]
55. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
56. 3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents.
Nayyar A; Malde A; Jain R; Coutinho E
Bioorg Med Chem; 2006 Feb; 14(3):847-56. PubMed ID: 16214351
[TBL] [Abstract][Full Text] [Related]
57. 3D-QSAR studies of some reversible Acetyl cholinesterase inhibitors based on CoMFA and ligand protein interaction fingerprints using PC-LS-SVM and PLS-LS-SVM.
Ghafouri H; Ranjbar M; Sakhteman A
Comput Biol Chem; 2017 Aug; 69():19-27. PubMed ID: 28544873
[TBL] [Abstract][Full Text] [Related]
58. Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA).
Xing L; Welsh WJ; Tong W; Perkins R; Sheehan DM
SAR QSAR Environ Res; 1999; 10(2-3):215-37. PubMed ID: 10491851
[TBL] [Abstract][Full Text] [Related]
59. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
